Mechanisms of diabetic nephropathy-old buddies and newcomers part 2

Experimental and Clinical Endocrinology and Diabetes

Volumn 118, Issue 10, 2010, Pages 667-672

  Nawroth, P P ^a   Isermann, B ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

diabetes; disease mechanisms; nephropathy

Indexed keywords

ANGIOPOIETIN 2; ICOSANOID; LIPID; THROMBOMODULIN; VASCULOTROPIN;

APOPTOSIS; DIABETIC NEPHROPATHY; GLOMERULUS FILTRATION; JUXTAGLOMERULAR CELL; MITOCHONDRION; PODOCYTE; PRIORITY JOURNAL; REVIEW;

ANIMALS; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; ENDOCRINOLOGY; HUMANS; KIDNEY; MOLECULAR TARGETED THERAPY; RESEARCH; SIGNAL TRANSDUCTION;

EID: 78349278880     PISSN: 09477349     EISSN: 14393646     Source Type: Journal    
DOI: 10.1055/s-0030-1253440     Document Type: Review

References (49)

1. Nakagawa T, Kosugi T, Haneda M, et al. Abnormal angiogenesis in diabetic nephropathy. Diabetes 2009 58 1471-1478
2. Baelde HJ, Eikmans M, Lappin DW, et al. Reduction of VEGF-A and CTGF expression in diabetic nephropathy is associated with podocyte loss. Kidney Int 2007 71 637-645
3. Eremina V, Baelde HJ, Quaggin SE. Role of the VEGF a signaling pathway in the glomerulus: evidence for crosstalk between components of the glomerular filtration barrier. Nephron Physiol 2007 106 32-37
4. Ku CH, White KE, Dei CA, et al. Inducible overexpression of sFlt-1 in podocytes ameliorates glomerulopathy in diabetic mice. Diabetes 2008 57 2824-2833
5. Nakagawa T. Uncoupling of the VEGF-endothelial nitric oxide axis in diabetic nephropathy: an explanation for the paradoxical effects of VEGF in renal disease. Am J Physiol Renal Physiol 2007 292 F1665-F1672
6. Neugebauer S, Baba T, Watanabe T. Association of the nitric oxide synthase gene polymorphism with an increased risk for progression to diabetic nephropathy in type 2 diabetes. Diabetes 2000 49 500-503
7. Zanchi A, Moczulski DK, Hanna LS, et al. Risk of advanced diabetic nephropathy in type 1 diabetes is associated with endothelial nitric oxide synthase gene polymorphism. Kidney Int 2000 57 405-413
8. Nakagawa T, Sato W, Glushakova O, et al. Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy. J Am Soc Nephrol 2007 18 539-550
9. Zhao HJ, Wang S, Cheng H, et al. Endothelial nitric oxide synthase deficiency produces accelerated nephropathy in diabetic mice. J Am Soc Nephrol 2006 17 2664-2669
10. Nakagawa T, Sato W, Sautin YY, et al. Uncoupling of vascular endothelial growth factor with nitric oxide as a mechanism for diabetic vasculopathy. J Am Soc Nephrol 2006 17 736-745
11. Davis B, Dei CA, Long DA, et al. Podocyte-specific expression of angiopoetin-2 causes proteinuria and apoptosis of glomerular endothelia. J Am Soc Nephrol 2007 18 2320-2329
12. Isermann B, Vinnikov IA, Madhusudhan T, et al. Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis. Nat Med 2007 13 1349-1358
13. Gilbert RE, Marsden PA. Activated protein C and diabetic nephropathy. N Engl J Med 2008 358 1628-1630
14. Isermann B, Hendrickson SB, Zogg M, et al. Endothelium-specific loss of murine thrombomodulin disrupts the protein C anticoagulant pathway and causes juvenile-onset thrombosis. J Clin Invest 2001 108 537-546
15. Weiler H, Isermann BH. Thrombomodulin. J Thromb Haemost 2003 1 1515-1524
16. Fujiwara Y, Tagami S, Kawakami Y. Circulating thrombomodulin and hematological alterations in type 2 diabetic patients with retinopathy. J Atheroscler Thromb 1998 5 21-28
17. Borcea V, Morcos M, Isermann B, et al. Influence of ramipril on the course of plasma thrombomodulin in patients with diabetes mellitus. Vasa 1999 28 172-180
18. Matsumoto K, Yano Y, Gabazza EC, et al. Inverse correlation between activated protein C generation and carotid atherosclerosis in Type 2 diabetic patients. Diabet Med 2007 24 1322-1328
19. Isermann B, Sood R, Pawlinski R, et al. The thrombomodulin-protein C system is essential for the maintenance of pregnancy. Nat Med 2003 9 331-337
20. Glaser CB, Morser J, Clarke JH, et al. Oxidation of a specific methionine in thrombomodulin by activated neutrophil products blocks cofactor activity. A potential rapid mechanism for modulation of coagulation. J Clin Invest 1992 90 2565-2573
21. Ceriello A, Esposito K, Ihnat M, et al. Simultaneous control of hyperglycemia and oxidative stress normalizes enhanced thrombin generation in type 1 diabetes. J Thromb Haemost 2009 7 1228-1230
22. Gupta A, Williams MD, Macias WL, et al. Activated Protein C and Acute Kidney Injury: Selective Targeting of PAR-1. Curr Drug Targets 2009
23. Kaneider NC, Leger AJ, Agarwal A, et al. Role reversal for the receptor PAR1 in sepsis-induced vascular damage. Nat Immunol 2007 8 1303-1312
24. Lassila M, Seah KK, Allen TJ, et al. Accelerated nephropathy in diabetic apolipoprotein e-knockout mouse: role of advanced glycation end products. J Am Soc Nephrol 2004 15 2125-2138
25. Gaede P, Lund-Andersen H, Parving HH, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008 358 580-591
26. Proctor G, Jiang T, Iwahashi M, et al. Regulation of renal fatty acid and cholesterol metabolism, inflammation, and fibrosis in Akita and OVE26 mice with type 1 diabetes. Diabetes 2006 55 2502-2509
27. Komers R, Lindsley JN, Oyama TT, et al. Cyclo-oxygenase-2 inhibition attenuates the progression of nephropathy in uninephrectomized diabetic rats. Clin Exp Pharmacol Physiol 2007 34 36-41
28. Abrahamian H, Endler G, Exner M, et al. Association of low-grade inflammation with nephropathy in type 2 diabetic patients: role of elevated CRP-levels and 2 different gene-polymorphisms of proinflammatory cytokines. Exp Clin Endocrinol Diabetes 2007 115 38-41
29. Galkina E, Ley K. Leukocyte recruitment and vascular injury in diabetic nephropathy. J Am Soc Nephrol 2006 17 368-377
30. Chow FY, Nikolic-Paterson DJ, Ozols E, et al. Intercellular adhesion molecule-1 deficiency is protective against nephropathy in type 2 diabetic db/db mice. J Am Soc Nephrol 2005 16 1711-1722
31. Xiao X, Ma B, Dong B, et al. Cellular and humoral immune responses in the early stages of diabetic nephropathy in NOD mice. J Autoimmun 2009 32 85-93
32. Moriya R, Manivel JC, Mauer M. Juxtaglomerular apparatus T-cell infiltration affects glomerular structure in Type 1 diabetic patients. Diabetologia 2004 47 82-88
33. Sato W, Kosugi T, Zhang L, et al. The pivotal role of VEGF on glomerular macrophage infiltration in advanced diabetic nephropathy. Lab Invest 2008 88 949-961
34. Tarabra E, Giunti S, Barutta F, et al. Effect of the monocyte chemoattractant protein-1/CC chemokine receptor 2 system on nephrin expression in streptozotocin-treated mice and human cultured podocytes. Diabetes 2009 58 2109-2118
35. Pezzolesi MG, Katavetin P, Kure M, et al. Confirmation of genetic associations at ELMO1 in the GoKinD collection supports its role as a susceptibility gene in diabetic nephropathy. Diabetes 2009 58 2698-2702
36. Russo LM, Sandoval RM, Campos SB, et al. Impaired tubular uptake explains albuminuria in early diabetic nephropathy. J Am Soc Nephrol 2009 20 489-494
37. Kato M, Zhang J, Wang M, et al. MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-beta-induced collagen expression via inhibition of E-box repressors. Proc Natl Acad Sci U S A 2007 104 3432-3437
38. Mahimainathan L, Das F, Venkatesan B, et al. Mesangial cell hypertrophy by high glucose is mediated by downregulation of the tumor suppressor PTEN. Diabetes 2006 55 2115-2125
39. Zhang Z, Peng H, Chen J, et al. MicroRNA-21 protects from mesangial cell proliferation induced by diabetic nephropathy in db/db mice. FEBS Lett 2009 583 2009-2014
40. Kato M, Putta S, Wang M, et al. TGF-beta activates Akt kinase through a microRNA-dependent amplifying circuit targeting PTEN. Nat Cell Biol 2009 11 881-889
41. Dai C, Stolz DB, Kiss LP, et al. Wnt/beta-catenin signalling promotes podocyte dysfunction and albuminuria. J Am Soc Nephrol 2009 20 1997-2008
42. Lee SH, Kim MH, Han HJ. Arachidonic acid potentiates hypoxia-induced VEGF expression in mouse embryonic stem cells: involvement of Notch, Wnt, and HIF-1alpha. Am J Physiol Cell Physiol 2009 297 C207-C216
43. Wang SN, Lapage J, Hirschberg R. Loss of tubular bone morphogenetic protein-7 in diabetic nephropathy. J Am Soc Nephrol 2001 12 2392-2399
44. Dolan V, Murphy M, Sadlier D, et al. Expression of gremlin, a bone morphogenetic protein antagonist, in human diabetic nephropathy. Am J Kidney Dis 2005 45 1034-1039
45. Wang S, Chen Q, Simon TC, et al. Bone morphogenic protein-7 (BMP-7), a novel therapy for diabetic nephropathy. Kidney Int 2003 63 2037-2049
46. Walsh DW, Roxburgh SA, McGettigan P, et al. Co-regulation of Gremlin and Notch signalling in diabetic nephropathy. Biochim Biophys Acta 2008 1782 10-21
47. Lee SH, Kim MH, Han HJ. Arachidonic acid potentiates hypoxia-induced VEGF expression in mouse embryonic stem cells: involvement of Notch, Wnt, and HIF-1alpha. Am J Physiol Cell Physiol 2009 297 C207-C216
48. Niranjan T, Bielesz B, Gruenwald A, et al. The Notch pathway in podocytes plays a role in the development of glomerular disease. Nat Med 2008 14 290-298
49. Walsh DW, Roxburgh SA, McGettigan P, et al. Co-regulation of Gremlin and Notch signalling in diabetic nephropathy. Biochim Biophys Acta 2008 1782 10-21